Skip to content

Inspection Record

Abeona Therapeutics Inc — FDA 483 Findings

US FDAInspected 2024-03-01Published 2026-10-26 4 findingsAseptic processing and sterility assuranceEquipment and facilityDeviation, CAPA, and investigation

Inspectors Ou Olivia MaThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Media and reagents (e.g., are not adequately controlled for quality prior to being used in the aseptic manufacturing process.

2Equipment and facility

Disinfectant efficacy studies performed to support the disinfectants used in the facility and during the manufacturing processes are deficient.

3Deviation, CAPA, and investigation

The inefficient management of deviations by Quality Assurance resulted in delayed investigations for which risk assessments were inadequate and adversely impacted final decisions and actions.

4Aseptic processing and sterility assurance

The aseptic manufacturing process lacks sufficient controls to ensure sterility of the prademagene zamikeracel final product, specifically: a.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Abeona Therapeutics Inc company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.